Trametinib

Generic Name
Trametinib
Brand Names
Mekinist, Spexotras
Drug Type
Small Molecule
Chemical Formula
C26H23FIN5O4
CAS Number
871700-17-3
Unique Ingredient Identifier
33E86K87QN
Background

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...

Indication

Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

It is used in combination with dabrafenib for the:
...

Associated Conditions
Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
Associated Therapies
-
Clinical Trials
Related News

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

First Posted Date
2017-02-27
Last Posted Date
2024-06-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
93
Registration Number
NCT03065387
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Phase 1
Active, not recruiting
Conditions
Melanoma
Interventions
Drug: Dabrafenib
Drug: Trametinib
Drug: Phenformin
First Posted Date
2017-01-20
Last Posted Date
2024-02-09
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
18
Registration Number
NCT03026517
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan Kettering Westchester, Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Phase 2
Terminated
Conditions
Melanoma
Brain Metastases
Interventions
Drug: Dabrafenib
Drug: Trametinib
First Posted Date
2016-11-28
Last Posted Date
2021-08-20
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
6
Registration Number
NCT02974803
Locations
🇨🇦

QEII Health Sciences Centre, Halifax, Nova Scotia, Canada

🇨🇦

Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada

🇨🇦

Odette Cancer Centre, Toronto, Ontario, Canada

and more 3 locations

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

First Posted Date
2016-11-28
Last Posted Date
2024-05-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
241
Registration Number
NCT02974725
Locations
🇸🇪

Novartis Investigative Site, Stockholm, Sweden

🇺🇸

Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States

🇺🇸

Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee, United States

and more 4 locations

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

First Posted Date
2016-11-18
Last Posted Date
2024-12-03
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
573
Registration Number
NCT02967692
Locations
🇺🇸

California Cancer Associates for Research and Excellence, Encinitas, California, United States

🇺🇸

UC Irvine Medical Center, Orange, California, United States

🇺🇸

Stanford Cancer Center, Stanford, California, United States

and more 15 locations

Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

Phase 1
Withdrawn
Conditions
Cancer
Interventions
Drug: Trametinib
First Posted Date
2016-10-20
Last Posted Date
2018-09-14
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT02939846

The Drug Rediscovery Protocol (DRUP Trial)

First Posted Date
2016-10-05
Last Posted Date
2024-01-24
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
1550
Registration Number
NCT02925234
Locations
🇳🇱

Meander medisch centrum, Amersfoort, Netherlands

🇳🇱

Netherlands Cancer Institute, Amsterdam, Netherlands

🇳🇱

Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

and more 33 locations

A Clinical Trial of Patients With Melanoma

First Posted Date
2016-09-27
Last Posted Date
2018-05-15
Lead Sponsor
University of Texas Southwestern Medical Center
Registration Number
NCT02915666
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

First Posted Date
2016-09-22
Last Posted Date
2024-10-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
52
Registration Number
NCT02910700
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

First Posted Date
2016-08-26
Last Posted Date
2023-05-01
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
14
Registration Number
NCT02881242
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy